Donor-derived cell-free DNA levels predict 3-year outcomes in kidney transplant recipients with stable function

Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker for detecting acute rejection in kidney transplant recipients, but its prognostic value in patients with stable graft function remains unclear. This study evaluated the association between dd-cfDNA levels and long-term clinical outcomes. We retrospectively analyzed 267 kidney transplant recipients with stable renal function between January 2020 and July 2023, stratified by plasma dd-cfDNA levels into three groups: A (<1%, n = 205), B (1–<2%, n = 34), and C (≥2%, n = 28). Each patient contributed a single index dd-cfDNA measurement obtained during routine outpatient follow-up, which defined baseline; the interval from transplantation to the index measurement did not differ among groups (p = 0.124). Clinical outcomes included changes in serum creatinine, incidence of adverse events, graft loss, patient mortality, and biopsy findings over three years. Creatinine levels remained stable in Group A but increased significantly in Groups B and C from baseline to year 3 (1.38 to 1.96 mg/dL, p < 0.0001; and 1.36 to 1.84 mg/dL, p = 0.0019, respectively). Adverse events were significantly more frequent in Groups B (41.2%) and C (42.9%) compared with Group A (9.8%, p < 0.001). Graft loss rates were 0.98%, 11.76%, and 7.14% in Groups A, B, and C, respectively (p = 0.002), and mortality showed a significant increasing trend across groups (p = 0.023). Elevated dd-cfDNA levels are associated with adverse long-term outcomes in kidney transplant recipients with stable graft function, suggesting that dd-cfDNA may serve as a valuable tool for early risk stratification and long-term monitoring in transplant care.

Authors

Institutions

Publication Details

Journal
Renal Failure
Published
2026-11-17
DOI
https://doi.org/10.1080/0886022x.2026.2751271
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Donor-derived cell-free DNA levels predict 3-year outcomes in kidney transplant recipients with stable function

Jinsong Chen, Tingya Jiang, Xuefeng Ni, Dongrui Cheng et al.
Renal Failure
Renal Transplantation Outcomes and Treatments
article

Donor-derived cell-free DNA levels predict 3-year outcomes in kidney transplant recipients with stable function

Jinsong Chen, Tingya Jiang, Xuefeng Ni, Dongrui Cheng, Cuello Garcia Haider, Li Xue, Zhou Yang, Xiaohui Xu, Kenan Xie
article en

Abstract

Donor-derived cell-free DNA (dd-cfDNA) is a promising noninvasive biomarker for detecting acute rejection in kidney transplant recipients, but its prognostic value in patients with stable graft function remains unclear. This study evaluated the association between dd-cfDNA levels and long-term clinical outcomes. We retrospectively analyzed 267 kidney transplant recipients with stable renal function between January 2020 and July 2023, stratified by plasma dd-cfDNA levels into three groups: A (<1%, n = 205), B (1–<2%, n = 34), and C (≥2%, n = 28). Each patient contributed a single index dd-cfDNA measurement obtained during routine outpatient follow-up, which defined baseline; the interval from transplantation to the index measurement did not differ among groups (p = 0.124). Clinical outcomes included changes in serum creatinine, incidence of adverse events, graft loss, patient mortality, and biopsy findings over three years. Creatinine levels remained stable in Group A but increased significantly in Groups B and C from baseline to year 3 (1.38 to 1.96 mg/dL, p < 0.0001; and 1.36 to 1.84 mg/dL, p = 0.0019, respectively). Adverse events were significantly more frequent in Groups B (41.2%) and C (42.9%) compared with Group A (9.8%, p < 0.001). Graft loss rates were 0.98%, 11.76%, and 7.14% in Groups A, B, and C, respectively (p = 0.002), and mortality showed a significant increasing trend across groups (p = 0.023). Elevated dd-cfDNA levels are associated with adverse long-term outcomes in kidney transplant recipients with stable graft function, suggesting that dd-cfDNA may serve as a valuable tool for early risk stratification and long-term monitoring in transplant care.

Renal FailureVol. 48(1)
Jiangsu University (CN), Nanjing General Hospital of Nanjing Military Command (CN), Viva Biotech (China) (CN), Nanjing University (CN)
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon